JI-101

TargetMol
Product Code: TAR-T3476
Supplier: TargetMol
CodeSizePrice
TAR-T3476-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-5mg5mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-1mL1 mL * 10 mM (in DMSO)£134.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-10mg10mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-25mg25mg£270.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-50mg50mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3476-100mg100mg£605.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).
CAS:
900573-88-8
Formula:
C22H20BrN5O2
Molecular Weight:
466.339
Pathway:
Tyrosine Kinase/Adaptors; Angiogenesis
Purity:
0.9941
SMILES:
COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12
Target:
VEGFR; PDGFR; Ephrin Receptor

References

S. D. Gurav, Jeniffer et al. Pharmacokinetics, Tissue Distribution and Identification of Putative Metabolites of JI-101 - A Novel Triple Kinase Inhibitor in Rats. Arzneimittelforschung 2012; 62(01): 27-34. Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-?, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs, December 2015, Volume 33, Issue 6, pp 1217-1224